Workers clean the windows of a building of Roche in Rotkreuz May 27, 2020. REUTERS/Arnd Wiegmann/File Photo

The United States Food and Drug Administration approved ROCHE HOLDING AG-BR's oral treatment for advanced breast cancer on Monday. The approval covers combination therapy for patients carrying an ESR1 mutation.